Evidence supporting European Medicines Agency drug approvals (2020–2023): A cross-sectional study of trial design and outcomes

Clinical Trials · Published 2026-04-07 · DOI 10.1177/17407745261437363

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1177/17407745261437363

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Covariate adjustment in randomized trials: An overview · Clinical Trials · 2026 · Same journal
• Covariate adjustment in randomized clinical trials: From general theory to practical insights · Clinical Trials · 2026 · Same journal
• Additional crossovers in cluster randomised crossover trials do not always increase statistical power · Clinical Trials · 2026 · Same journal
• Patient notification about pragmatic clinical trials conducted with a waiver of consent: A qualitative study · Clinical Trials · 2025 · Same journal
• A review of use of external data and update on reporting standards in Sequential Multiple-Assignment Randomised Trials · Clinical Trials · 2025 · Same journal
• Shaping the future of clinical trials through strategic foresight · Clinical Trials · 2026 · Same journal
• Bayesian design and analysis of two-arm cluster randomised trials using assurance: Extension to binary outcomes and comparison of Markov chain Monte Carlo and Integrated Nested Laplace Approximations · Clinical Trials · 2026 · Same journal
• Surrogate markers used as efficacy endpoints in NIH-sponsored clinical trials · Clinical Trials · 2026 · Same journal
• Confirmatory evidence supporting single pivotal trial new drug approvals by the Food and Drug Administration, 2015 through 2023 · Clinical Trials · 2025 · Same journal
• Topic-specific living databases of clinical trials: A scoping review of public databases · Clinical Trials · 2026 · Same journal